Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of AcromegalyMcLaren · The Journal of Clinical Endocrinology & Metabolism2022PDF147 KB
Prospect of Acromegaly Therapy: Molecular Mechanism of Clinical Drugs Octreotide and PaltusotineZhao · Nature Communications2023PDF3.4 MB
Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 AgonistZhao · ACS Medicinal Chemistry Letters2022PDF2.0 MB
Protogrammoceras paltum (Buckman), a late Pliensbachian (Jurassic) ammonite from Axel Heiberg Island, Canadian Arctic ArchipelagoHall · NRC Research Press1983PDF797 KB
Paltusotine, a Novel Oral Once-daily Nonpeptide SST2 Receptor Agonist, Suppresses GH and IGF-1 in Healthy VolunteersMadan · Pituitary2022PDF766 KB
Über Aminoalkoholester von Hydroxyboranen, VIII. Einfluss von Substituenten in 3-Stellung des triptych-Boroxazolidins auf die Geschwindigkeit der SN-B-paltungStump · European Journal of Organic Chemistry1963PDF297 KB
8404 Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or LanreotideGadelha · Journal of the Endocrine Society2024PDF68 KB
OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor LigandsGadelha · Journal of the Endocrine Society2023PDF64 KB